Use of minocycline in viral infections

Indian Journal of Medical Research

Volumn 133, Issue 5, 2011, Pages 467-470

  Dutta, Kallol ^a   Basu, Anirban ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

Antibiotic; Neurodegenerative diseases; Viral infections

Indexed keywords

ANTIBIOTIC AGENT; MINOCYCLINE; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALPHA VIRUS; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DRUG COST; DRUG EFFECT; DRUG MARKETING; DRUG SAFETY; DRUG USE; ENCEPHALOMYELITIS; FLAVIVIRIDAE INFECTION; FLAVIVIRUS; FLAVIVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; JAPANESE ENCEPHALITIS VIRUS; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REOVIRUS; REVIEW; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS INHIBITION; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MINOCYCLINE; VIRUS DISEASES;

EID: 79958051292     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74: 727-9.
2. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs. 2003; 5: 301-13.
3. eMedExpert.com -Comprehensive Information on Prescription Drugs. (Updated: January 07, 2010). Available from: http://www.emedexpert.com/facts/minocycline-facts.shtml. accessed on June 18, 2010.
4. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122: 81-9.
5. Gelber RH, Fukuda K, Byrd S, Murray LP, Siu P, Tsang M, et al. A clinical trial of minocycline in lepromatous leprosy. BMJ 1992; 304: 91-2.
6. Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14: 852-61.
7. Carney S, Butcher RA, Dawborn JK, Pattison G. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol 1974; 1: 299-308.
8. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95: 15769-74.
9. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-10.
10. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-26.
11. Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma (In Press) 2010.
12. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004; 10: 679-86.
13. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004; 63: 547-9.
14. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-51.
15. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53.
16. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Minocycline in patients with Huntington's disease. (Updated: June 23, 2005). Available from: http://clinicaltrials.gov/ct2/show/NCT00029874; accessed on June 21, 2010.
17. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI). (Updated: February 11, 2010). Available from: http://clinicaltrials.gov/ct2/show/NCT01058395, accessed on June 21, 2010.
18. ClinicalTrialsFeeds.gov. A service of the U.S. National Institutes of Health. Safety and Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study. (Updated: May 26, 2010) Available from: http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01133080, accessed on June 21, 2010.
19. Lemaitre M, Guetard D, Henin Y, Montagnier L, Zerial A. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res Virol 1990; 141: 5-16.
20. Si Q, Cosenza M, Kim MO, Zhao ML, Brownlee M, Goldstein H, et al. A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004; 10: 284-92.
21. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293: 2003-11.
22. Follstaedt SC, Barber SA, Zink MC. Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 2008; 14: 376-88.
23. Jenwitheesuk E, Samudrala R. Identification of potential HIV-1 targets of minocycline. Bioinformatics 2007; 23: 2797-9.
24. Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis, 2010; 201: 1132-40.
25. Ratai EM, Bombardier JP, Joo CG, Annamalai L, Burdo TH, Campbell J, et al. Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One 2010; 5: e10523.
26. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Minocycline for HIV+ Cognitive Impairment in Uganda. (Updated: May 26, 2010). Available from: http://clinicaltrials.gov/ct2/show/NCT00855062, accessed on June 21, 2010.
27. Michaelis M, Kleinschmidt MC, Doerr HW, Cinatl J Jr. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother 2007; 60: 981-6.
28. Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem 2008; 105: 1582-95.
29. Mishra MK, Ghosh D, Duseja R, Basu A. Antioxidant potential of minocycline in Japanese Encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. neurochem Int 2009; 54: 464-70.
30. Mishra MK, Dutta K, Saheb SK, Basu A. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem Int 2009; 55: 717-23.
31. Clinical Trials Registry- India. A service of the Indian Council of Medical Research. Randomised Double Blind Controlled Trial of Minocycline in Japanese encephalitis. (Updated: January 11, 2011). Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=2529&EncHid=&userName=minocycline, accessed on April 18, 2011.
32. Irani DN, Prow NA. Neuroprotective interventions targeting detrimental host immune responses protect mice from fatal alphavirus encephalitis. J Neuropathol Exp Neurol 2007; 66: 533-44.
33. Richardson-Burns SM, Tyler KL. Minocycline delays disease onset and mortality in reovirus encephalitis. Exp Neurol 2005; 192: 331-9.
34. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645-6.